Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a Hybrid design to primarily assess effectiveness, and to secondarily observe and collect data on the implementation of the service. This will allow the assessment of health-related outcomes and implementation outcomes to facilitate dissemination and replication if proven to be successful in other CBOs in Thailand, regionally, and globally.
Implementation Effectiveness To assess effectiveness, an interrupted time series (ITS) design. The counterfactual scenario (under which KP-led HCV test and treat had not been implemented) will be determined using routine service data collected from 15 months prior to the study implementation, and will provide a comparison for the evaluation of the impact of KP-led HCV test and treat by examining any change occurring in the primary outcomes in the post-implementation period during the 15 months of the study.
Implementation Strategies To assess implementation, Proctor's model was used to guide the selection of relevant implementation outcomes, which during this stage of implementation are acceptability, feasibility, and fidelity. Socio-ecological level, framework, and relevant constructs for each outcome are outlined below and in table 1.
Acceptability of KP-led HCV test and treat Acceptability refers to the perception that the service is agreeable and satisfactory. It will be measured using surveys at four socio-ecological levels, informed by different frameworks according to relevance
Feasibility of providing KP-led HCV test and treat by KP-lay providers in CBOs
Feasibility refers to the extent to which the service can be successfully delivered within the CBO setting. It will be measured at two socio-ecological levels:
Fidelity of KP-led HCV test and treat implementation Fidelity refers to the extent to which the service was delivered as intended. It will be measured at the provider level using observation, checklists, and assessment of client records, guided by CFIR.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Implementation for anti-HCV reactive client | Experimental | All clients who test anti-HCV positive at the study CBOs will be assessed for the inclusion criteria. Eligible clients will be informed and offered to participate in the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KP-Led HCV test and treat service | Other | After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation. Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of eligible clients initiating DAAs | The proportion of eligible clients initiating DAAs in CBOs under KP-led HCV test and treat in CBOs as compared to pre-implementation. | 18 months |
| The proportion of complete tretmented client | The proportion of clients who complete 12 weeks of treatment under KP-led HCV test and treat in CBOs as compared to pre-implementation. | 18 months |
| The proportion of SVR achieved client | The proportion of clients who achieve SVR at 12 weeks after treatment completion under KP-led HCV test and treat in CBOs as compared to pre-implementation. | 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| The HCV re-infection rates | Proportion of clients with HCV-reinfection among those who had previously achieved SVR | 18 months |
| The duration to DAA initiation among clients with chronic HCV infection |
Not provided
Eligibility criteria for assessment of effectiveness outcomes:
Inclusion Criteria:
Exclusion Criteria:
Eligibility criteria assessment of implementation outcomes:
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rainbow Sky Association of Thailand (RSAT) | Bangkok | Bangkapi | 10240 | Thailand | ||
| Institute of HIV Research and Innovation |
Not provided
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Time from anti-HCV positivity to DAA initiation among clients with chronic HCV infection pre- compared to post-implementation
| 18 months |
| The acceptability of KP-led HCV test and treat | The acceptability of KP-led HCV test and treat will be measured via survey and/or in-depth interviews with clients, providers, CBO leadership, and policymakers | 18 months |
| Provider perception of KP-led HCV test and treat feasibility. | The feasibility of providing KP-led HCV test and treat will be measured via survey and/or in-depth interviews with KP-lay providers. | 18 months |
| The fidelity of provider during the implementation | The KP-led HCV test and treat fidelity of KP-lay providers will be assessed through service delivery checklists and case report forms. | 18 months |
| Pathum Wan |
| Bangkok |
| 10330 |
| Thailand |
| The Service Workers In Group Foundation (SWING) | Bangkok | Building 3, Patpong, Surawong Road | 10500 | Thailand |
| MPLUS Foundation (MPLUS) | Chiang Mai | 50100 | Thailand |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |